RESPECT PFO Clinical TrialThe purpose of this study is to investigate whether percutaneous Patent Foramen Ovale (PFO) closure, using the AMPLATZER PFO Occluder, is superior to current standard of care medical treatment in the prevention of recurrent embolic stroke. Principal Investigator Philip A. TealBody Locations and Systems StrokeArea VancouverAge 18-60
Dabigatran Following Transient Ischemic Attack and Minor Stroke (DATAS II)Rationale: To date, anticoagulant therapy in acute stroke has also been limited by excess hemorrhagic events. The oral anticoagulant dabigatran is a novel agent, which has been shown to be associated with much lower intracranial hemorrhage rates. Principal Investigator Thalia FieldBody Locations and Systems StrokeArea VancouverAge 18 and above
A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion (TEMPO-2)This trial will enroll patients that have been diagnosed with a transient ischemic attack (TIA) or minor stroke that has occurred within the past 12 hours. Anyone diagnosed with a minor stroke faces the possibility of long-term disability and even death, regardless of treatment. Principal Investigator Thalia FieldBody Locations and Systems Stroke, StrokeArea VancouverAge 18 and above
Hyperbaric Oxygen Post Established Stroke (HOPES)The purpose of this study is to examine the role of Hyperbaric Oxygen Therapy (HBOT) in improving neurological function in patients who are 6 to 36 months post ischemic stroke. Principal Investigator David W. HarrisonBody Locations and Systems StrokeArea VancouverAge 19-85
AMPLATZER™ LAA Occluder Post Approval Study (PAS)The AMPLATZER LAA Occluder is a transcatheter, self-expanding nitinol device intended for use in preventing thrombus embolization from the LAA. Principal Investigator Jacqueline SawBody Locations and Systems Atrial Fibrillation, StrokeArea VancouverAge 18 and above
